Regenerative Medical Technology (RMTG) Profit After Tax (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Profit After Tax of -$876274.0 for Q1 2026, down 15.29% year-over-year from -$1.0 million in Q1 2025, and up 37.09% quarter-over-quarter from -$1.4 million in Q4 2025.
Regenerative Medical Technology (RMTG) Profit After Tax (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's Profit After Tax history runs 9 years deep, the most recent figure standing at -$876274.0 for Q1 2026.
- In Q1 2026, Profit After Tax fell 15.29% year-over-year to -$876274.0; the TTM figure through Mar 2026 stood at -$7.9 million (down 81.77% YoY), while the FY2025 annual figure was -$7.8 million, down 40.44% from the prior year.
- Profit After Tax for Q1 2026 stood at -$876274.0, up from -$1.4 million in the prior quarter.
- The five-year high for Profit After Tax was -$256037.0 in Q4 2023, with the low at -$5.9 million in Q3 2023.
- The 5-year median for Profit After Tax is -$1.4 million (2025), against an average of -$1.7 million.
- The sharpest annual moves came in 2022 and 2025: Profit After Tax surged 86.44% in 2022, then plunged 390.76% in 2025.
- Regenerative Medical Technology's Profit After Tax stood at -$992760.0 in 2022, then surged by 74.21% to -$256037.0 in 2023, then sank by 149.26% to -$638186.0 in 2024, then slumped by 118.25% to -$1.4 million in 2025, then jumped by 37.09% to -$876274.0 in 2026.
- Business Quant data shows RMTG's Profit After Tax at -$876274.0 in Q1 2026, -$1.4 million in Q4 2025, and -$4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -16.62 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -876,274.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -876,274.00 |
| Dec 31, 2025 | -1.39 Mn |
| Sep 30, 2025 | -4.35 Mn |
| Jun 30, 2025 | -1.31 Mn |
| Mar 31, 2025 | -760,039.00 |
| Dec 31, 2024 | -638,186.00 |
| Sep 30, 2024 | -887,146.00 |
| Jun 30, 2024 | -2.08 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | -256,037.00 |
| Sep 30, 2023 | -5.86 Mn |
| Jun 30, 2023 | -2.03 Mn |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | -992,760.00 |
| Sep 30, 2022 | -1.34 Mn |
| Jun 30, 2022 | -1.49 Mn |
| Mar 31, 2022 | -1.68 Mn |
| Dec 31, 2021 | -1.57 Mn |
| Sep 30, 2021 | -9.92 Mn |
| Jun 30, 2021 | -926,077.00 |